According to the latest research report titled ‘North America Breast Cancer Therapeutics Market Forecast 2028 By Therapy, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, North America breast cancer therapeutics market is expected to amass a valuation of USD 16 billion by 2028.

Growing prevalence of breast cancer, penetration of several diagnostic & screening programs, advancements in breast cancer drugs, and mounting investments in research & development are the major factors fueling North America breast cancer therapeutics market development.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4966049/  

In addition, supportive reimbursement policies are likely positively impact the growth trajectory of the industry in the forthcoming years.

Despite the positive outlook, side effects associated with breast cancer drugs as well as their expensive nature may impede renumeration scope of the industry during the analysis timeframe.

Based on therapy, targeted therapy segment is likely to progress at a CAGR of 7.8% during the forecast period, as it is the most promising area of research that directly targets tumor cells and kills them instead of adversely degrading healthy cells, which is usually the case with conventional broad-spectrum chemotherapy and radiation procedures.

On the other hand, the chemotherapy segment of North America breast cancer therapeutics industry held a 9% revenue share in 2021and is expected to surpass a valuation of USD 1.3 billion by the end of 2028, as chemotherapy is the standard treatment option individually or in combination with other medications for HER2+ breast cancer and triple negative breast cancer.

From a geographical standpoint, the U.S. industry amassed a valuation of USD 9.3 billion in 2021 and is poised to rise exponentially during the assessment timeframe, due to the burgeoning prevalence of the disease among women in the nation.

To minimize the pervasiveness of the disease, President Joe Biden introduced a program dubbed as ‘Cancer Moonshot’ in 2016, which he relaunched in 2022 to accelerate cancer research. The program raised a funding of USD 1.8 million since its launch and aims to reduce fatality rates of cancer by a staggering 50% over the next twenty-five years.

The competitive terrain of North America breast cancer therapeutics marketplace is defined by major players such as Eisai Co. Ltd., Sanofi S.A., Merck & Co. Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb, Amgen Inc., Novartis International AG, Pfizer Inc., Eli Lilly & Company, and AstraZeneca plc.